Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

PHASE3RecruitingINTERVENTIONAL
Enrollment

354

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Alzheimer DiseaseNeurofibrillary Tangle
Interventions
DRUG

XTR006

all patients will receive one injection of \[18F\]XTR006, a PET radiopharmaceutical selective for NFTs. For the injection, subjects will receive a target dose of 4-6 mCi IV as a bolus injection. \[18F\]XTR006 injection will be followed by a 10 ml saline flush.

Trial Locations (1)

100089

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Sinotau Pharmaceutical Group

INDUSTRY